TY - JOUR
T1 - Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones
AU - Tew, Ben Yi
AU - Legendre, Christophe
AU - Schroeder, Mark A.
AU - Triche, Tim
AU - Gooden, Gerald C.
AU - Huang, Yizhou
AU - Butry, Loren
AU - Ma, Daniel J.
AU - Johnson, Kyle
AU - Martinez, Rae Anne
AU - Pierobon, Mariaelena
AU - Petricoin, Emanuel F.
AU - O'Shaughnessy, Joyce
AU - Osborne, Cindy
AU - Tapia, Coya
AU - Buckley, David N.
AU - Glen, Jennifer
AU - Bernstein, Mark
AU - Sarkaria, Jann N.
AU - Toms, Steven A.
AU - Salhia, Bodour
N1 - Publisher Copyright:
© 2019 The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: [email protected].
PY - 2020/1/11
Y1 - 2020/1/11
N2 - Background: The dearth of relevant tumor models reflecting the heterogeneity of human central nervous system metastasis (CM) has hindered development of novel therapies. Methods: We established 39 CM patient-derived xenograft (PDX) models representing the histological spectrum, and performed phenotypic and multi-omic characterization of PDXs and their original patient tumors. PDX clonal evolution was also reconstructed using allele-specific copy number and somatic variants. Results: PDXs retained their metastatic potential, with flank-implanted PDXs forming spontaneous metastases in multiple organs, including brain, and CM subsequent to intracardiac injection. PDXs also retained the histological and molecular profiles of the original patient tumors, including retention of genomic aberrations and signaling pathways. Novel modes of clonal evolution involving rapid expansion by a minor clone were identified in 2 PDXs, including CM13, which was highly aggressive in vivo forming multiple spontaneous metastases, including to brain. These PDXs had little molecular resemblance to the patient donor tumor, including reversion to a copy number neutral genome, no shared nonsynonymous mutations, and no correlation by gene expression. Conclusions: We generated a diverse and novel repertoire of PDXs that provides a new set of tools to enhance our knowledge of CM biology and improve preclinical testing. Furthermore, our study suggests that minor clone succession may confer tumor aggressiveness and potentiate brain metastasis.
AB - Background: The dearth of relevant tumor models reflecting the heterogeneity of human central nervous system metastasis (CM) has hindered development of novel therapies. Methods: We established 39 CM patient-derived xenograft (PDX) models representing the histological spectrum, and performed phenotypic and multi-omic characterization of PDXs and their original patient tumors. PDX clonal evolution was also reconstructed using allele-specific copy number and somatic variants. Results: PDXs retained their metastatic potential, with flank-implanted PDXs forming spontaneous metastases in multiple organs, including brain, and CM subsequent to intracardiac injection. PDXs also retained the histological and molecular profiles of the original patient tumors, including retention of genomic aberrations and signaling pathways. Novel modes of clonal evolution involving rapid expansion by a minor clone were identified in 2 PDXs, including CM13, which was highly aggressive in vivo forming multiple spontaneous metastases, including to brain. These PDXs had little molecular resemblance to the patient donor tumor, including reversion to a copy number neutral genome, no shared nonsynonymous mutations, and no correlation by gene expression. Conclusions: We generated a diverse and novel repertoire of PDXs that provides a new set of tools to enhance our knowledge of CM biology and improve preclinical testing. Furthermore, our study suggests that minor clone succession may confer tumor aggressiveness and potentiate brain metastasis.
KW - Animal model
KW - Central nervous system metastasis
KW - Clonal evolution
KW - Patient-derived xenograft
UR - http://www.scopus.com/inward/record.url?scp=85077776924&partnerID=8YFLogxK
U2 - 10.1093/neuonc/noz137
DO - 10.1093/neuonc/noz137
M3 - Article
C2 - 31433055
AN - SCOPUS:85077776924
SN - 1522-8517
VL - 22
SP - 70
EP - 83
JO - Neuro-Oncology
JF - Neuro-Oncology
IS - 1
ER -